Global CAR-T cell therapy market is expected to reach USD6134.56 million by 2026, growing at a CAGR of 33.11% over the forecast period. The growth in the market can be attributed to increasing prevalence of cancer and growing pool of patients who are showing response failure towards alternative treatments. Rising clinical trials and development of new and effective therapy options is also acting as key growth driver for global CAR-T cell therapy market. In addition to this, growing need for breakthrough therapeutic solutions and effectiveness of CAR-T cell therapy in treating cancer are expected to fuel the market growth through 2026.

Moreover, thriving immuno-oncology sector and increasing R&D expenditure are expected to positively influence the growth of global CAR-T cell therapy market. However, global CAR-T cell therapy market might also face some challenges. The side effects of CAR-T cell therapy may lead to neurological problems and cytokine release syndrome (CRS), which might hamper the market growth. Also, the complicated manufacturing process of CAR-T cells makes it a costly treatment.

Global CAR-T cell therapy market can be segmented based on product type, tumor type, indication, treatment type, targeted antigen, end user, company and region. Based on indication, the market can be segmented into Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle cell lymphoma (MCL) and others. Among them, Acute Lymphoblastic Leukemia (ALL) segment is expected to witness the fastest CAGR during the forecast period owing to its high prevalence around the globe.

Regionally, North America dominated the global CAR-T cell therapy market in 2020 and is further expected to hold its dominance during the forecast period owing to increasing development and launch of new therapies for the treatment of cancer by key healthcare and drug manufacturers in the region. Further, Europe is expected to be the second largest market for global CAR-T cell therapy through 2026 as the region is witnessing extensive research for development of cancer treatment therapies.

Major companies operating in global CAR-T cell therapy market include Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Co., Cellectis SA, Amgen Inc., Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc., Novartis AG, Poseida Therapeutics Inc., Johnson & Johnson SA, Allogene Therapeutics Inc., Autolus Therapeutics PLC, Humanigen Inc., Sangamo Therapeutics, Inc., among others. The market players are investing on extensive research & development activities to launch new CAR-T Cell therapies to strengthen their positions in global market.

Years considered for this report:

Historical Years: 2017-2019

Base Year: 2020

Estimated Year: 2021E

Forecast Period: 2022F–2026F

Objective of the Study:

  • To analyze the historical growth in the market size of global CAR-T cell therapy market from 2017 to 2020.
  • To estimate and forecast the market size of global CAR-T Cell Therapy market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global CAR-T Cell Therapy market based on product type, tumor type, indication, treatment type, by targeted antigen, by end user, company and regional distribution.
  • To identify drivers and challenges for global CAR-T cell therapy market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global CAR-T cell therapy market.
  • To identify and analyze the profile of leading players operating in the global CAR-T cell therapy market.

Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of CAR-T cell therapy companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated the global CAR-T cell therapy market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • CAR-T cell therapy drug manufacturers/ companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as CAR-T cell therapy drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global CAR-T cell therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global CAR-T Cell Therapy Market, By Product Type:
    • Yescarta (axicabtagene ciloleucel)
    • Kymriah (tisagenlecleucel) 
    • Tecartus (brexucabtagene autoleucel)
    • Breyanzi (lisocabtagene maraleucel)
    • Abecma (idecabtagene vicleucel)
    • Others
  • Global CAR-T Cell Therapy Market, By Tumor Type
    • Hematological Malignancies
    • Solid Tumors
  • Global CAR-T Cell Therapy Market, By Indication:
    • Diffused Large B-cell Lymphoma (DLBCL)
    • Acute Lymphoblastic Leukemia (ALL)
    • Follicular Lymphoma (FL)
    • Mantle Cell Lymphoma (MCL)
    • Others
  • Global CAR-T Cell Therapy Market, By Treatment Type
    • Single Treatment
    • Combination Treatment
  • Global CAR-T Cell Therapy Market, By Targeted Antigen:
    • CD 19
    • BCMA (B-Cell Maturation Antigen)
    • Others
  • Global CAR-T Cell Therapy Market, By End User:
    • Hospitals
    • Speciality Clinics
    • Ambulatory Surgical Centers
    • Others
  • Global CAR-T Cell Therapy Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • Japan
      • China
      • India 
      • South Korea
      • Australia
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

Profit margin analysis in case of direct and indirect sales channel.

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global CAR-T Cell Therapy Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Brand Awareness

5.2.  Unmet Need and Challenges

5.3.  Factors Driving the CAR-T Cell Therapy Market

6.    Global CAR-T Cell Therapy Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others)

6.2.2.     By Tumor Type (Hematological Malignancies, Solid Tumors)

6.2.3.     By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

6.2.4.     By Treatment Type (Single Treatment, Combination Treatment)

6.2.5.     By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)

6.2.6.     By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

6.2.7.     By Company (2020)

6.2.8.     By Region

6.3.  Product Market Map

7.    North America CAR-T Cell Therapy Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Tumor Type

7.2.2.     By Indication

7.2.3.     By Treatment Type

7.2.4.     By Targeted Antigen

7.2.5.     By End User

7.2.6.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States CAR-T Cell Therapy Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Tumor Type

7.3.1.2.2.             By Indication

7.3.1.2.3.             By Treatment Type

7.3.1.2.4.             By Targeted Antigen

7.3.1.2.5.             By End User

7.3.2.     Canada CAR-T Cell Therapy Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Tumor Type

7.3.2.2.2.             By Indication

7.3.2.2.3.             By Treatment Type

7.3.2.2.4.             By Targeted Antigen

7.3.2.2.5.             By End User

7.3.3.     Mexico CAR-T Cell Therapy Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Tumor Type

7.3.3.2.2.             By Indication

7.3.3.2.3.             By Treatment Type

7.3.3.2.4.             By Targeted Antigen

7.3.3.2.5.             By End User

8.    Europe CAR-T Cell Therapy Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Tumor Type

8.2.2.     By Indication

8.2.3.     By Treatment Type

8.2.4.     By Targeted Antigen

8.2.5.     By End User

8.2.6.     By Country

8.3.  Europe: Country Analysis

8.3.1.     Germany CAR-T Cell Therapy Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Tumor Type

8.3.1.2.2.             By Indication

8.3.1.2.3.             By Treatment Type

8.3.1.2.4.             By Targeted Antigen

8.3.1.2.5.             By End User

8.3.2.     France CAR-T Cell Therapy Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Tumor Type

8.3.2.2.2.             By Indication

8.3.2.2.3.             By Treatment Type

8.3.2.2.4.             By Targeted Antigen

8.3.2.2.5.             By End User

8.3.3.     United Kingdom CAR-T Cell Therapy Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Tumor Type

8.3.3.2.2.             By Indication

8.3.3.2.3.             By Treatment Type

8.3.3.2.4.             By Targeted Antigen

8.3.3.2.5.             By End User

8.3.4.     Italy CAR-T Cell Therapy Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Tumor Type

8.3.4.2.2.             By Indication

8.3.4.2.3.             By Treatment Type

8.3.4.2.4.             By Targeted Antigen

8.3.4.2.5.             By End User

8.3.5.     Spain CAR-T Cell Therapy Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Tumor Type

8.3.5.2.2.             By Indication

8.3.5.2.3.             By Treatment Type

8.3.5.2.4.             By Targeted Antigen

8.3.5.2.5.             By End User

9.    Asia-Pacific CAR-T Cell Therapy Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Tumor Type

9.2.2.     By Indication

9.2.3.     By Treatment Type

9.2.4.     By Targeted Antigen

9.2.5.     By End User

9.2.6.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     Japan CAR-T Cell Therapy Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Tumor Type

9.3.1.2.2.             By Indication

9.3.1.2.3.             By Treatment Type

9.3.1.2.4.             By Targeted Antigen

9.3.1.2.5.             By End User

9.3.2.     China CAR-T Cell Therapy Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Tumor Type

9.3.2.2.2.             By Indication

9.3.2.2.3.             By Treatment Type

9.3.2.2.4.             By Targeted Antigen

9.3.2.2.5.             By End User

9.3.3.     India CAR-T Cell Therapy Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Tumor Type

9.3.3.2.2.             By Indication

9.3.3.2.3.             By Treatment Type

9.3.3.2.4.             By Targeted Antigen

9.3.3.2.5.             By End User

9.3.4.     South Korea CAR-T Cell Therapy Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Tumor Type

9.3.4.2.2.             By Indication

9.3.4.2.3.             By Treatment Type

9.3.4.2.4.             By Targeted Antigen

9.3.4.2.5.             By End User

9.3.5.     Australia CAR-T Cell Therapy Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Tumor Type

9.3.5.2.2.             By Indication

9.3.5.2.3.             By Treatment Type

9.3.5.2.4.             By Targeted Antigen

9.3.5.2.5.             By End User  

10.  South America CAR-T Cell Therapy Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Tumor Type

10.2.2.  By Indication

10.2.3.  By Treatment Type

10.2.4.  By Targeted Antigen

10.2.5.  By End User

10.2.6.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil CAR-T Cell Therapy Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Tumor Type

10.3.1.2.2.           By Indication

10.3.1.2.3.           By Treatment Type

10.3.1.2.4.           By Targeted Antigen

10.3.1.2.5.           By End User

10.3.2.  Argentina CAR-T Cell Therapy Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Tumor Type

10.3.2.2.2.           By Indication

10.3.2.2.3.           By Treatment Type

10.3.2.2.4.           By Targeted Antigen

10.3.2.2.5.           By End User

10.3.3.  Colombia CAR-T Cell Therapy Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Tumor Type

10.3.3.2.2.           By Indication

10.3.3.2.3.           By Treatment Type

10.3.3.2.4.           By Targeted Antigen

10.3.3.2.5.           By End User

11.  Middle East and Africa CAR-T Cell Therapy Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Tumor Type

11.2.2.  By Indication

11.2.3.  By Treatment Type

11.2.4.  By Targeted Antigen

11.2.5.  By End User

11.2.6.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa CAR-T Cell Therapy Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Tumor Type

11.3.1.2.2.           By Indication

11.3.1.2.3.           By Treatment Type

11.3.1.2.4.           By Targeted Antigen

11.3.1.2.5.           By End User

11.3.2.  Saudi Arabia CAR-T Cell Therapy Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Tumor Type

11.3.2.2.2.           By Indication

11.3.2.2.3.           By Treatment Type

11.3.2.2.4.           By Targeted Antigen

11.3.2.2.5.           By End User

11.3.3.  UAE CAR-T Cell Therapy Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Tumor Type

11.3.3.2.2.           By Indication

11.3.3.2.3.           By Treatment Type

11.3.3.2.4.           By Targeted Antigen

11.3.3.2.5.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  Gilead Sciences Inc.

14.2.2.  AbbVie Inc.

14.2.3.  Bristol Myers Squibb Co.

14.2.4.  Cellectis SA

14.2.5.  Amgen Inc.

14.2.6.  Pfizer Inc.

14.2.7.  Merck & Co. Inc.

14.2.8.  Intellia Therapeutics Inc.

14.2.9.  Novartis AG

14.2.10. Poseida Therapeutics Inc.

14.2.11. Johnson & Johnson SA

14.2.12. Allogene Therapeutics Inc.

14.2.13. Autolus Therapeutics PLC

14.2.14. Humanigen Inc

14.2.15. Sangamo Therapeutics, Inc.

15.  Strategic Recommendations

16.  About Us & Disclaimer

  • Figure 1:           Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 2:           Global CAR-T Cell Therapy Market Share, By Product Type, By Value, , 2017-2026F

    Figure 3:           Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 4:           Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 5:           Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 6:           Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 7:           Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 8:           Global CAR-T Cell Therapy Market Share, By Company, By Value, 2020

    Figure 9:           Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2026F

    Figure 10:         Global CAR-T Cell Therapy Product Market Map, By Value, 2017-2026F

    Figure 11:         North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 12:         North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 13:         North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 14:         North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 15:         North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 16:         North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 17:         North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F

    Figure 18:         United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 19:         United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 20:         United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 21:         United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 22:         United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 23:         United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 24:         Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 25:         Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 26:         Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 27:         Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 28:         Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 29:         Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 30:         Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 31:         Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 32:         Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 33:         Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 34:         Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 35:         Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 36:         Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 37:         Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 38:         Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 39:         Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 40:         Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 41:         Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 42:         Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F

    Figure 43:         Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 44:         Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 45:         Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 46:         Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 47:         Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 48:         Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 49:         France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 50:         France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 51:         France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 52:         France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 53:         France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 54:         France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 55:         United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 56:         United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 57:         United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 58:         United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 59:         United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 60:         United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 61:         Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 62:         Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 63:         Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 64:         Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 65:         Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 66:         Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 67:         Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 68:         Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 69:         Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 70:         Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 71:         Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 72:         Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 73:         Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 74:         Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 75:         Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 76:         Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 77:         Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 78:         Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 79:         Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F

    Figure 80:         Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 81:         Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 82:         Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 83:         Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 84:         Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 85:         Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 86:         China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 87:         China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 88:         China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 89:         China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 90:         China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 91:         China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 92:         India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 93:         India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 94:         India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 95:         India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 96:         India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 97:         India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 98:         South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 99:         South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 100:       South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 101:       South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 102:       South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 103:       South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 104:       Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 105:       Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 106:       Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 107:       Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 108:       Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 109:       Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 110:       South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 111:       South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 112:       South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 113:       South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 114:       South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 115:       South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 116:       South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F

    Figure 117:       Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 118:       Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 119:       Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 120:       Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 121:       Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 122:       Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 123:       Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 124:       Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 125:       Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 126:       Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 127:       Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 128:       Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 129:       Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 130:       Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F

    Figure 131:       Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F

    Figure 132:       Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F

    Figure 133:       Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F

    Figure 134:       Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F

    Figure 135:       Middle East and Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F

    Figure 136:       Middle East and Africa CAR-T Cell Therapy M